Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8371 to 8385 of 8989 results

  1. Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]

    Discontinued Reference number: GID-TA10363

    Technology appraisal guidance
    Discontinued

  2. Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

    Discontinued Reference number: GID-TA10295

    Technology appraisal guidance
    Discontinued

  3. Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355]

    Discontinued Reference number: GID-TA10321

    Technology appraisal guidance
    Discontinued

  4. Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]

    Discontinued Reference number: GID-TA10244

    Technology appraisal guidance
    Discontinued

  5. Lifitegrast for treating dry eye disease [ID1229]

    Discontinued Reference number: GID-TA10196

    Technology appraisal guidance
    Discontinued

  6. Pacritinib for treating myelofibrosis [ID880]

    Discontinued Reference number: GID-TA10133

    Technology appraisal guidance
    Discontinued

  7. Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

    Discontinued Reference number: GID-TA10377

    Technology appraisal guidance
    Discontinued

  8. Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

    Discontinued Reference number: GID-TA10271

    Technology appraisal guidance
    Discontinued

  9. Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]

    Discontinued Reference number: GID-TA10158

    Technology appraisal guidance
    Discontinued

  10. Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

    Discontinued Reference number: GID-TA10566

    Technology appraisal guidance
    Discontinued

  11. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued Reference number: GID-TA10072

    Technology appraisal guidance
    Discontinued

  12. Melanoma (advanced, unresectable, metastatic, NRAS mutation positive) - binimetinib [ID833]

    Discontinued Reference number: GID-TA10074

    Technology appraisal guidance
    Discontinued

  13. Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer [ID1429]

    Discontinued Reference number: GID-TA10512

    Technology appraisal guidance
    Discontinued

  14. Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]

    Discontinued Reference number: GID-TA10416

    Technology appraisal guidance
    Discontinued

  15. Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]

    Discontinued Reference number: GID-TA10221

    Technology appraisal guidance
    Discontinued